A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
Genre
Journal articleDate
2022-03-01Author
Joudi, MaryamMoradi Binabaj, Maryam
Porouhan, Pejman
PeyroShabany, Babak
Tabasi, Mohsen
FAZILATPANAH, DANIAL

Khajeh, Mahtab
Mehrabian, Arezoo
Dehghani, Mansoureh
Welsh, James S.
Keykhosravi, Batol
Akbari Yazdi, Azam
Ariamanesh, Mona
Ghasemi, Ahmad
Ferns, Gordon
Alireza Javadinia, Seyed
Group
Center for Inflammation and Lung Research (Temple University)Subject
Breast cancerInactivated SARS-CoV-2 vaccine
Seroconversion
SARS-CoV2
COVID-19 vaccine
Cancer
Malignancy
Iran
Permanent link to this record
http://hdl.handle.net/20.500.12613/7555
Metadata
Show full item recordDOI
https://doi.org/10.3389/fendo.2022.798975Abstract
Aim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects. Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively. Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.Citation
Joudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, Khajeh M, Mehrabian A, Dehghani M, Welsh JS, Keykhosravi B, Akbari Yazdi A, Ariamanesh M, Ghasemi A, Ferns G and Javadinia SA (2022) A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome? Front. Endocrinol. 13:798975. doi: 10.3389/fendo.2022.798975Citation to related work
Frontiers MediaHas part
Frontiers in Endocrinology, Vol. 13ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/7533